Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access study of everolimus in metastatic renal cell carcinoma after VEGF receptor tyrosine kinase inhibitor failure
2007-005460-28Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus in renal cell carcinoma (RCC), sponsored by Novartis. Primary endpoint: Safety. Started May 2008; status: completed.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2007-005460-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005460-28.